Author:
Rasch Stine,Hansen Charlotte Toftmann,Abilgaard Niels
Abstract
Current guidelines recommend screening with serum M-protein and serum-free light chain analysis (S-FLC) when an M-protein-related disorder is suspected. Many patients with multiple myeloma will be overlooked if only serum M-protein is measured. Despite this, the general practitioners in some areas of Denmark cannot order S-FLC. This review aims to disseminate knowledge of the S-FLC analysis, its applicability, and limitations in the diagnostic workup for suspected monoclonal gammopathies.
Publisher
Danish Medical Association
Reference30 articles.
1. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group;Myeloma Working Group;Br J Haematol,2003
2. Derman B, Castillo JJ, Sarosiek S, Beksac M. When a monoclonal gammopathy is not multiple myeloma. Am Soc Clin Oncol Educ Book. 2022;42:1-10. https://doi.org/10.1200/EDBK_349643
3. Danske Multidisciplinære Cancer Grupper, Regionernes Kliniske Kvalitetsudviklingsprogram (RKKP). Diagnostik og opfølgning af myelomatose, 2023. https://www.dmcg.dk/Kliniske-retningslinjer/kliniske-retningslinjer-opdelt-paa-dmcg/myelomatose/diagnostik-og-opfolgning-af-myelomatose/ (17. juni 2024).
4. McTaggart MP, Lindsay J, Kearney EM. Replacing urine protein electrophoresis with serum free light chain analysis as a first-line test for detecting plasma cell disorders offers increased diagnostic accuracy and potential health benefit to patients. Am J Clin Pathol. 2013;140(6):890-7. https://doi.org/10.1309/AJCP25IHYLEWCAHJ
5. Sarto C, Intra J, Fania C et al. Monoclonal free light chain detection and quantification: performances and limits of available laboratory assays. Clin Biochem. 2021;95:28-33. https://doi.org/10.1016/j.clinbiochem.2021.05.006